Monitoring the Effects and Managing the Side Effects of Anticoagulation during Pregnancy

Obstetrics and Gynecology Clinics of North America

Volumn 33, Issue 3, 2006, Pages 397-411

  Gris, Jean Christophe ^a,b   Lissalde Lavigne, Géraldine ^a   Quére, Isabelle ^a   Marés, Pierre ^a  

^a DEPARTMENT OF NEUROLOGY   (France)

^b UNIV MONTPELLIER   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; ANTIVITAMIN K; BLOOD CLOTTING FACTOR 10; BLOOD CLOTTING FACTOR 10A; BLOOD CLOTTING FACTOR 10A INHIBITOR; BLOOD CLOTTING FACTOR 5; BLOOD CLOTTING FACTOR 7; BLOOD CLOTTING FACTOR 8; COUMARIN; D DIMER; DALTEPARIN; DANAPAROID; ENOXAPARIN; HEPARIN; HEPARIN DERIVATIVE; HEPARINOID; LOW MOLECULAR WEIGHT HEPARIN; PENTASACCHARIDE; PHOSPHOLIPID ANTIBODY; PROTAMINE SULFATE; PROTHROMBIN; PYRIDINE DERIVATIVE; RECOMBINANT BLOOD CLOTTING FACTOR 7A; THROMBIN INHIBITOR; THROMBOPLASTIN; TINZAPARIN; TRYPTASE; UNINDEXED DRUG; WARFARIN;

ANAPHYLACTIC SHOCK; ANGIONEUROTIC EDEMA; ARTHUS PHENOMENON; BLEEDING; BRONCHOSPASM; DELAYED HYPERSENSITIVITY; DRUG CROSS REACTIVITY; DRUG EFFICACY; DRUG ERUPTION; DRUG HYPERSENSITIVITY; DRUG MONITORING; DRUG SAFETY; ECZEMA; ERYTHEMA; FEMALE; HEMATOMA; HEPARIN INDUCED THROMBOCYTOPENIA; HUMAN; HYPOTENSION; IMMEDIATE TYPE HYPERSENSITIVITY; MACULOPAPULAR RASH; MUCOSAL DISEASE; OSTEOPOROSIS; POSTPARTUM HEMORRHAGE; PREGNANCY; PREGNANCY COMPLICATION; PREGNANCY OUTCOME; PRIORITY JOURNAL; RASH; REVIEW; SIDE EFFECT; SKIN ALLERGY; SKIN MANIFESTATION; SKIN NECROSIS; THROMBOCYTOPENIA; THROMBOSIS PREVENTION; URTICARIA; VASCULITIS; VENOUS THROMBOEMBOLISM; WOUND HEMORRHAGE;

ABNORMALITIES, DRUG-INDUCED; ANTICOAGULANTS; DERMATITIS, ALLERGIC CONTACT; FEMALE; FIBRINOLYTIC AGENTS; HEMORRHAGE; HEPARIN; HUMANS; PREGNANCY; PREGNANCY COMPLICATIONS, HEMATOLOGIC; THROMBOCYTOPENIA; THROMBOPHILIA; VENOUS THROMBOSIS; VITAMIN K;

EID: 33748482354     PISSN: 08898545     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ogc.2006.05.004     Document Type: Review

References (51)

1. Hall J.G., Pauli R.M., and Wilson K.M. Maternal and fetal sequelae of anticoagulation during pregnancy. Am J Med 68 (1980) 122-140
2. Iturbe-Alessio I., del Carmen Fonseca M., Mutchinik O., et al. Risks of anticoagulant therapy in pregnant women with artificial heart valves. N Engl J Med 315 (1986) 1390-1393
3. Ginsberg J.S., and Hirsh J. Use of anticoagulants during pregnancy. Chest 95 Suppl 2 (1989) 156S-160S
4. Wesseling J., van Driel D., and Heymans H.A.S. Coumarins during pregnancy: long term effects on growth and development in school age children. Thromb Haemost 85 (2001) 609-613
5. van Driel D., Wesseling J., ter Huurne K., et al. Adherence to a guideline for coumarins in pregnancy. Pharm World Sci 26 (2004) 297-300
6. Bates S.M., Greer I.A., Hirsh J., et al. Use of antithrombotic agents during pregnancy. Chest 126 (2004) 627S-644S
7. Sbarouni E., and Oakley C.M. Outcome of pregnancy in women with valve prostheses. Br Heart J 71 (1994) 196-201
8. Chan W.S., Anand S., and Ginsberg J.S. Anticoagulation of pregnant women with mechanical heart valves: a systematic review of the literature. Arch Intern Med 160 (2000) 191-196
9. Lind S.E., Callas P.W., Golden E.A., et al. Plasma levels of factors II, VII and X and their relationship to the international normalized ratio during chronic warfarin therapy. Blood Coagul Fibrinolysis 8 (1997) 48-53
10. Forestier F., Daffos F., and Capella-Pavlovsky M. Low molecular weight heparin (PK 10169) does not cross the placenta during the second trimester of pregnancy study by direct fetal blood sampling under ultrasound. Thromb Res 34 (1984) 557-560
11. Forestier F., Daffos F., Rainaut M., et al. Low molecular weight heparin (CY 216) does not cross the placenta during the third trimester of pregnancy. Thromb Haemost 57 (1987) 234
12. Omri A., Delaloye J.F., Andersen H., et al. Low molecular weight heparin Novo (LHN-1) does not cross the placenta during the second trimester of pregnancy. Thromb Haemost 61 (1989) 55-56
13. Forestier F., Sole Y., Aiach M., et al. Absence of transplacental passage of fragmin (Kabi) during the second and the third trimesters of pregnancy. Thromb Haemost 67 (1992) 180-181
14. Harenberg J., Schneider D., Heilmann L., et al. Lack of anti-factor Xa activity in umbilical cord vein samples after subcutaneous administration of heparin or low molecular mass heparin in pregnant women. Haemostasis 23 (1993) 314-320
15. Priollet P., Roncato M., Aiach M., et al. Low-molecular-weight heparin in venous thrombosis during pregnancy. Br J Haematol 63 (1986) 605-606
16. Harenberg J., Leber G., Zimmermann R., et al. Prevention of thromboembolism with low-molecular weight heparin in pregnancy. Geburtshilfe Frauenheilkd 47 (1987) 15-18
17. Baudot N., Roncato M., Vayssairat M., et al. Pregnancy in a patient with congenital protein S deficiency: the value of low molecular weight heparin. Presse Med 17 (1988) 1761
18. de Boer K., Heyboer H., ten Cate J.W., et al. Low molecular weight heparin treatment in a pregnant woman with allergy to standard heparins and heparinoid. Thromb Haemos 61 (1989) 148
19. Melissari E., Parker C.J., Wilson N.V., et al. Use of low molecular weight heparin in pregnancy. Thromb Haemost 68 (1992) 652-656
20. Hunt B.J., Doughty H.A., Majumdar G., et al. Thromboprophylaxis with low molecular weight heparin (Fragmin) in high risk pregnancies. Thromb Haemost 77 (1997) 39-43
21. Sanson B.J., Lensing A.W., Prins M.H., et al. Safety of low-molecular-weight heparin in pregnancy: a systematic review. Thromb Haemost 81 (1999) 668-672
22. Greer I.A., and Nelson-Piercy C. Low-molecular-weight heparins for thromboprophylaxis and treatment of venous thromboembolism in pregnancy: a systematic review of safety and efficacy. Blood 106 (2005) 401-407
23. Hirsh J., and Lee A.Y.Y. How we diagnose and treat deep vein thrombosis. Blood 99 (2002) 3102-3110
24. Levine M.N., Hirsh J., Gent M., et al. A randomized trial comparing activated thromboplastin time with heparin assay in patients with acute venous thromboembolism requiring large daily doses of heparin. Arch Intern Med 154 (1994) 49-56
25. Bates S.M., and Ginsberg J.S. How we manage venous thromboembolism during pregnancy. Blood 100 (2002) 3470-3478
26. Greaves M. Limitations of the laboratory monitoring of heparin therapy. Thromb Haemost 87 (2002) 163-164
27. Kitchen S., Lampietro R., Woolley A.M., et al. Anti-Xa monitoring during treatment with low molecular weight heparin or danaparoid: inter-assay variability. Thromb Haemost 82 (1999) 1289-1293
28. Bounameaux H., and de Moerloose P. Is laboratory monitoring of low-molecular-weight heparin therapy necessary? No. J Thromb Haemost 2 (2004) 551-554
29. Bombeli T., Raddatz Mueller P., and Fehr J. Evaluation of an optimal dose of low-molecular-weight heparin for thromboprophylaxis in pregnant women at risk of thrombosis using coagulation activation markers. Haemostasis 31 (2001) 90-98
30. Sarig G., Blumenfeld Z., Leiba R., et al. Modulation of systemic hemostatic parameters by enoxaparin during gestation in women with thrombophilia and pregnancy loss. Thromb Haemost 94 (2005) 980-985
31. Brenner B., Bar J., Ellis M., et al. Live-Enox Investigators. Effects of enoxaparin on late pregnancy complications and neonatal outcome in women with recurrent pregnancy loss and thrombophilia: results from the Live-Enox study. Fertil Steril 84 (2005) 770-773
32. Gris J.C., Mercier E., Quere I., et al. Low-molecular-weight heparin versus low-dose aspirin in women with one fetal loss and a constitutional thrombophilic disorder. Blood 103 (2004) 3695-3699
33. Bais J.M., Eskes M., Pel M., et al. Postpartum hemorrhage in nulliparous women: incidence and risk factors in low and high risk women: a Dutch population-based cohort study on standard (> or = 500 ml) and severe (> or = 1000 ml) postpartum hemorrhage. Eur J Obstet Gynecol Reprod Biol 115 (2004) 166-172
34. Ginsberg J.S., Kowalchuk G., Hirsh J., et al. Heparin therapy during pregnancy: risks to the fetus and mother. Arch Intern Med 149 (1989) 2233-2236
35. Burrows R.F., and Kelton J.G. Thrombocytopenia at delivery: a prospective survey of 6715 deliveries. Am J Obstet Gynecol 162 (1990) 731-734
36. van Besien K., Hoffman R., and Golichowski A. Pregnancy associated with lupus anticoagulant and heparin induced thrombocytopenia: management with a low molecular weight heparinoid. Thromb Res 62 (1991) 23-29
37. Bourhim M., Darnige L., Legallais C., et al. Anti-beta2-glycoprotein I antibodies recognizing platelet factor 4-heparin complex in antiphospholipid syndrome in patient substantiated with mouse model. J Mol Recognit 16 (2003) 125-130
38. Pettila V., Leinonen P., Markkola A., et al. Postpartum bone mineral density in women treated for thromboprophylaxis with unfractionated heparin or LMW heparin. Thromb Haemos 87 (2002) 182-186
39. Wawrzynska L., Tomkowski W.Z., Przedlacki J., et al. Changes in bone density during long-term administration of low-molecular-weight heparins or acenocoumarol for secondary prophylaxis of venous thromboembolism. Pathophysiol Haemost Thromb 33 (2003) 64-67
40. Handschin A.E., Trentz O.A., Hoerstrup S.P., et al. Effect of low molecular weight heparin (dalteparin) and fondaparinux (Arixtra) on human osteoblasts in vitro. Br J Surg 92 (2005) 177-183
41. Carlin A.J., Farquharson R.G., Quenby S.M., et al. Prospective observational study of bone mineral density during pregnancy: low molecular weight heparin versus control. Hum Reprod 19 (2004) 1211-1214
42. Hartvigsen J., Christensen K., Frederiksen H., et al. Genetic and environmental contributions to back pain in old age: a study of 2,108 Danish twins aged 70 and older. Spine 29 (2004) 897-901
43. Grimes J.P., and Wimalawansa S.J. Breastfeeding and postmenopausal osteoporosis. Curr Womens Health Rep 3 (2003) 193-198
44. Horleker T.T. Low molecular weight heparin and neuroaxial anesthesia. Thromb Res 101 (2002) V141-V154
45. Warkentin T.E., Roberts R.S., Hirsh J., et al. Heparin-induced skin lesions and other unusual sequelae of the heparin-induced thrombocytopenia syndrome: a nested cohort study. Chest 127 (2005) 1857-1861
46. Gaigl Z., Pfeuffer P., Raith P., et al. Tolerance to intravenous heparin in patients with delayed-type hypersensitivity to heparins: a prospective study. Br J Haematol 128 (2005) 389-392
47. Lagrange F., Brun J.L., Vergnes M.C., et al. Fondaparinux sodium does not cross the placental barrier: study using the in-vitro human dually perfused cotyledon model. Clin Pharmacokinet 41 Suppl 2 (2002) 47-49
48. Koch P. Delayed-type hypersensitivity skin reactions due to heparins and heparinoids: tolerance of recombinant hirudins and of the new synthetic anticoagulant fondaparinux. Contact Dermatitis 49 (2003) 276-280
49. Warkentin T.E., and Greinacher A. Heparin-induced thrombocytopenia: recognition, treatment, and prevention: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 126 Suppl (2004) 311S-337S
50. Magnani H.N. Heparin-induced thrombocytopenia (HIT): an overview of 230 patients treated with orgaran (Org 10172). Thromb Haemost 70 (1993) 554-561
51. Lindhoff-Last E., Kreutzenbeck H.J., and Magnani H.N. Treatment of 51 pregnancies with danaparoid because of heparin intolerance. Thromb Haemost 93 (2005) 63-69